Compare SXC & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXC | AURA |
|---|---|---|
| Founded | 1960 | 2007 |
| Country | United States | United States |
| Employees | 848 | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 733.1M | 713.4M |
| IPO Year | 2011 | 2021 |
| Metric | SXC | AURA |
|---|---|---|
| Price | $7.75 | $7.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $9.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 1.4M | 661.7K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.17% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,600,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.30 | N/A |
| 52 Week Low | $5.52 | $4.73 |
| 52 Week High | $9.74 | $9.54 |
| Indicator | SXC | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 37.60 | 63.14 |
| Support Level | $7.70 | $5.18 |
| Resistance Level | $8.47 | $7.81 |
| Average True Range (ATR) | 0.34 | 0.50 |
| MACD | -0.17 | 0.12 |
| Stochastic Oscillator | 6.90 | 99.37 |
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.